Technical Analysis for AIM - AIM ImmunoTech Inc.

Grade Last Price % Change Price Change
F 0.38 13.64% 0.05
AIM closed up 13.64 percent on Monday, March 18, 2024, on 2.39 times normal volume.
Earnings due: Mar 29
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 13.64%
Jack-in-the-Box Bearish Bearish Swing Setup 13.64%
Lower Bollinger Band Walk Weakness 13.64%
Inside Day Range Contraction 13.64%

   Recent Intraday Alerts

Alert Time
Rose Above 10 DMA about 10 hours ago
20 DMA Resistance about 10 hours ago
2x Volume Pace about 10 hours ago
1.5x Volume Pace about 10 hours ago
Up 2 ATRs about 10 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

AIM ImmunoTech Inc. Description

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Disease Acid Infectious Diseases Health Care Melanoma Pancreatic Cancer Hepatitis B Carcinoma HIV Interferon Renal Cell Carcinoma Treatment Of Hepatitis Treatment Of Hepatitis B Chronic Fatigue Syndrome

Is AIM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

See more AIM news...

Indicators

Indicator Value
52 Week High 0.7487
52 Week Low 0.3201
Average Volume 149,748
200-Day Moving Average 0.50
50-Day Moving Average 0.41
20-Day Moving Average 0.39
10-Day Moving Average 0.37
Average True Range 0.03
RSI (14) 46.24
ADX 26.38
+DI 18.28
-DI 22.19
Chandelier Exit (Long, 3 ATRs) 0.34
Chandelier Exit (Short, 3 ATRs) 0.41
Upper Bollinger Bands 0.44
Lower Bollinger Band 0.33
Percent B (%b) 0.39
BandWidth 27.09
MACD Line -0.02
MACD Signal Line -0.02
MACD Histogram -0.0029
Fundamentals Value
Market Cap 18.32 Million
Num Shares 48.8 Million
EPS -0.43
Price-to-Earnings (P/E) Ratio -0.87
Price-to-Sales 100.75
Price-to-Book 0.89
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.48
Resistance 3 (R3) 0.48 0.44 0.46
Resistance 2 (R2) 0.44 0.41 0.44 0.46
Resistance 1 (R1) 0.41 0.40 0.42 0.41 0.45
Pivot Point 0.37 0.37 0.38 0.37 0.37
Support 1 (S1) 0.34 0.34 0.35 0.34 0.30
Support 2 (S2) 0.30 0.33 0.30 0.29
Support 3 (S3) 0.27 0.30 0.29
Support 4 (S4) 0.27